<DOC>
	<DOCNO>NCT00000634</DOCNO>
	<brief_summary>To generate initial information pharmacokinetics ( blood level ) dose proportionality nevirapine ( BI-RG-587 ) plasma level HIV-infected child ; ass safety tolerance single rise oral dos nevirapine HIV-infected child ; confirm single dos achieve certain plasma level adult achieve similar level HIV-infected child . Test tube study show nevirapine ( BI-RG-587 ) inhibit replication ( reproduction ) HIV . Nevirapine work zidovudine ( AZT ) active strain virus resistant AZT . Studies drug HIV-infected adult show serious adverse effect .</brief_summary>
	<brief_title>A Pilot Pharmacokinetic Phase I Evaluation BI-RG-587 HIV-Infected Children</brief_title>
	<detailed_description>Test tube study show nevirapine ( BI-RG-587 ) inhibit replication ( reproduction ) HIV . Nevirapine work zidovudine ( AZT ) active strain virus resistant AZT . Studies drug HIV-infected adult show serious adverse effect . Two dos , give mouth , evaluate : Three patient receive low dose , 7 day third patient receives low dose , three additional patient receive high dose . After dose , blood drawn 1 , 2 , 4 , 8 , 24 , 48 , 96 , 168 hour measure blood level drug .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Intravenous gammaglobulin . Pneumocystis prophylaxis accord publish guideline . Patients must follow : HIV infection . Parent guardian must available give write informed consent . Exclusion Criteria Concurrent Medication : Excluded : Zidovudine ( AZT ) . Steroid dependency . Excluded within 1 hour 4 hour study drug administration : Drugs might interfere absorption study drug ( H2 blocker , antacid , carafate , cholestyramine ) . Benzodiazepines . Alcoholcontaining substance . Concurrent Treatment : Excluded : Requiring supplemental oxygen . Patients follow exclude : Active opportunistic serious bacterial infection . Lymphoid interstitial pneumonitis ( LIP ) steroid dependent require supplemental oxygen pretreatment pa02 &lt; 70 mm Hg . Preexisting malignancy . Prior Medication : Excluded : Zidovudine ( AZT ) within 7 day prior administration study drug . Excluded least 4 week prior drug administration : Other approve investigational antiretroviral agent . All investigational agent . Biologic response modifier ( e.g. , interferon ) immunomodulators . Immunosuppressive agent ( include glucocorticoid ) . Coumadin anticoagulant medication . Prior Treatment : Excluded : Red blood cell transfusion within 4 week study entry . Patients may follow : Opportunistic serious bacterial infection . Zidovudine ( AZT ) &gt; 7 day prior administration study drug . Active alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Benzodiazepines</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drugs , Investigational</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>